trending Market Intelligence /marketintelligence/en/news-insights/trending/kXhhJ0DI0WoK2EfrzEb2pQ2 content esgSubNav
In This List

AbbVie arthritis drug meets endpoint in phase 3 trial

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


AbbVie arthritis drug meets endpoint in phase 3 trial

AbbVie Inc. said its investigational drug upadacitinib met its primary endpoint in a phase 3 trial.

The company was evaluating the drug in patients with moderate to severe rheumatoid arthritis who did not adequately respond to prior therapy.

More than half the patients achieved a 20% improvement at week 12 of the trial, compared to 36% of patients who received placebo. Low disease activity was achieved by 48% of patients, compared to the 17% on placebo.

The drug is also being investigated to treat Crohn's disease, ulcerative colitis and atopic dermatitis.

Phase 3 trials of upadacitinib in psoriatic arthritis are also ongoing.